The clinical assessment of the myocardial damage caused by anthracyclin (ANT)-therapy is difficult. Therefore a study was performed to evaluate non-invasive markers of anthracyclin-induced cardiac effects, with emphasis on course-to-course variation.
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy.
CHDR
Broeyer FJ, Osanto S, Ritsema van Eck HJ, van Steijn AQ, Ballieux BE, Schoemaker RC, Cohen AF, Burggraaf J
